FDA OKs an in­haled ver­sion of smok­ing ces­sa­tion drug Chan­tix — for a com­mon eye dis­ease

Oys­ter Point Phar­ma now has its first FDA-ap­proved prod­uct — Tyr­vaya. And the biotech has tak­en a unique route to get there by us­ing an old drug with a sto­ried past.

The New Jer­sey biotech an­nounced this morn­ing that the FDA has ap­proved their nasal spray prod­uct for dry eye dis­ease on Fri­day — the first nasal spray to be ap­proved for the dis­ease. The prod­uct’s ac­tive in­gre­di­ent is 0.03 mg of vareni­cline, al­so known as smok­ing ces­sa­tion aid Chan­tix.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER